Clinical Insights: May 10, 2023
Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Mydcombi™ (phenylephrine hydrochloride and tropicamide) Ophthalmic Spray – New Drug Approval – May 5, 2023 – Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technology company developing the Optejet® device for…
Clinical Insights: May 3, 2023
Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Lumryz™ (sodium oxybate) – formerly FT218 – New Drug Approval – May 1, 2023 – Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform…
Tune Into Our Latest 340B Insider Podcast Episode!
In the episode “Client Success – Best Practices for Maintaining & Optimizing a 340B Program,” we are joined by RxStrategies’ Christina Breckenridge and Katie Gemma. As Senior Directors of Client Success and 340B experts, they partner with entities of all sizes to implement best practices, share the latest insights, and drive overall program success. Walk…
Clinical Insights: April 26, 2023
Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval No new update. New Indication/Dosage/Formulation Approval Polivy® (polatuzumab vedotin-piiq) – New Label Expansion – April 19, 2023 – The Food and Drug Administration approved polatuzumab vedotin-piiq (Polivy®, Genentech, Inc.)…
Let’s Connect: The 340B Grantees Spring Conference
WILL WE SEE YOU AT THE 340B GRANTEES SPRING CONFERENCE? RxStrategies’ VP of Contract Pharmacy, Rhodie Smith, looks forward to connecting with industry leaders during the 340B Grantees Spring Conference in New Orleans, LA, May 3-5. The conference provides a platform for 340B Grantees like Ryan White Clinics, Federally Qualified Health Centers (FQHCs), and FQHC…
Clinical Insights: April 19, 2023
Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Omisirge® (omidubicel-onlv) Suspension for Infusion – New Drug Approval – April 17, 2023 – The U.S. Food and Drug Administration approved Omisirge® (omidubicel-onlv), a substantially modified allogeneic (donor) cord…
Clinical Insights: April 12, 2023
Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval No new update. New Indication/Dosage/Formulation Approval No new update. New Drug Shortage April 10, 2023 Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets (Currently in Shortage) April 06,…
Clinical Insights: April 5, 2023
Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval No new update. New Indication/Dosage/Formulation Approval Padcev®(enfortumab vedotin-ejfv) and Keytruda®(pembrolizumab) for Injection – New Label Expansion – April 3, 2023 – The Food and Drug Administration granted accelerated approval…
Clinical Insights: March 29, 2023
Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Joenja® (leniolisib) Tablets – New Drug Approval – March 24, 2023 – FDA has approved Joenja® (leniolisib) tablets as the first treatment for activated phosphoinositide 3-kinase delta syndrome in adult…
Clinical Insights: March 22, 2023
Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval No new update. New Indication/Dosage/Formulation Approval Tafinlar® (dabrafenib) – New Label Expansion – March 16, 2023 – The Food and Drug Administration approved dabrafenib (Tafinlar®, Novartis) with trametinib (Mekinist®,…
Clinical Insights: March 15, 2023
Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Daybue™ (trofinetide) Oral Solution – New Drug Approval – March 10, 2023 – Acadia Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration (FDA) has approved Daybue™ (trofinetide)…
Clinical Insights: March 8, 2023
Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Skyclarys™ (omaveloxolone) Capsules – New Orphan Drug Approval – February 28, 2023 – FDA has approved Skyclarys™ (omaveloxolone) as the first treatment for Friedreich’s ataxia, a rare, inherited, degenerative…